Sinfonia Biotherapeutics is pioneering the development of precision therapies for genetically-defined dementia and related neurodegenerative diseases.
Frontotemporal dementia (FTD) and Parkinson’s disease are devastating diseases that rob people of their personality, ability to function and behavior. There is a huge unmet medical need for effective treatments, yet there are still no drug therapies to halt these diseases. The biologic therapies we are developing to treat these devastating diseases are delivered using our clinical-stage bioreactor directly to affected brain tissues.
We have three treatments in preclinical development: iProg Progranulin therapy is in development for the treatment of Progranulin-related FTD and GBA1 Parkinson's disease. PMTA, a multi-targeted therapy, is in development for GBA1-associated Parkinson’s disease, and LMTA, a multi-targeted therapy, is in development for GBA1-associated Lewy body dementia.
We have a core team of industry veterans with deep expertise in drug and device development for neurodegenerative and orphan diseases.
Our web site is under construction. Please contact us to learn more about what we are doing to develop precision therapies for frontotemporal dementia or other neurodegenerative disorders.
